Protagonist Therapeutics (PTGX) Price & Analysis

Compare

687 Followers

PTGX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$33.31 - $60.60

Previous CloseN/A

Volume120.35K

Average Volume (3M)657.73K

Market Cap

$3.49B

Enterprise Value$2.95B

Total Cash (Recent Filing)$570.47M

Total Debt (Recent Filing)$11.28M

Price to Earnings (P/E)78.9

Beta0.81

Next Earnings

Nov 05, 2025

EPS Estimate

-0.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.55

Shares Outstanding62,211,320

10 Day Avg. Volume641,437

30 Day Avg. Volume657,734

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.85

Enterprise Value/Revenue14.49

Enterprise Value/Gross Profit14.54

Enterprise Value/Ebitda116.19

Forecast

1Y Price Target

$69.20

Price Target Upside23.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Drug Approval And Market PotentialThe NDA for icotrokinra in patients with severe plaque psoriasis is supported by 4 pivotal Phase 3 studies, indicating strong data backing its approval.

Innovative TreatmentsRusfertide is viewed as a 'practice-changing' novel treatment in Polycythemia Vera with potential to become part of the standard of care.

Market ExpansionIcotrokinra is expected to achieve blockbuster status in psoriasis and capture significant market share in ulcerative colitis and psoriatic arthritis.

Bears Say

Competitive LandscapeThe compelling data in ulcerative colitis should support clinical development in Crohn's disease, opening up significant opportunities in inflammatory bowel disease.

Financial MilestonesPTGX is entitled to $35M upon the NDA filing for icotrokinra and $50M upon FDA approval, after which the tiered royalties that PTGX will receive on net product sales will range from 6% to 10%.

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP

Citizens JMP raised the firm’s price target on Protagonist Therapeutics (PTGX) to $69 from $67 and keeps an...

13d ago

PTGX

Protagonist Therapeutics files automatic mixed securities shelf

16:48 EDT Protagonist Therapeutics (PTGX) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

14d ago

PTGX

Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)

Reports Q2 revenue $5.5M, consensus $8.32M. “Thus far, 2025 has been a year of breakthrough accomplishments for Protagonist,...

14d ago

PTGX

Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating

Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Protagonist Therapeutics, retaining the price target of...

12d ago

PTGX

Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera

Protagonist Therapeutics Inc (($PTGX)) announced an update on their ongoing clinical study. Protagonist Therapeutics Inc. has recently completed...

13d ago

PTGX

Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment

Protagonist Therapeutics Inc (($PTGX)) announced an update on their ongoing clinical study. Protagonist Therapeutics Inc. is conducting a...

13d ago

PTGX

Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Protagonist Therapeutics, retaining the price target of $70.00....

13d ago

PTGX

Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress

Protagonist Therapeutics Inc ( ($PTGX) ) has released its Q2 earnings. Here is a breakdown of the information...

13d ago

PTGX

Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating

Protagonist Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tara Bancroft from...

13d ago

PTGX

Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus

Protagonist Therapeutics Inc (($PTGX)) announced an update on their ongoing clinical study. Protagonist Therapeutics Inc. is conducting a...

14d ago

PTGX

Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra

BTIG analyst Julian Harrison maintained a Buy rating on Protagonist Therapeutics yesterday and set a price target of...

29d ago

PTGX

Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Protagonist Therapeutics. The associated price target remains...

30d ago

PTGX

Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA

Protagonist Therapeutics (PTGX) announced the submission of a new drug application to the FDA by Johnson & Johnson...

1M ago

JNJ

PTGX

Protagonist announces NDA submission by Johnson & Johnson for icotrokinra

Protagonist Therapeutics (PTGX) announced the submission of a New Drug Application to the U.S. Food and Drug Administration...

1M ago

JNJ

PTGX

PTGX FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was $33.31 and its highest was $60.60 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is $3.49B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 77 days.

How were Protagonist Therapeutics’s earnings last quarter?

Protagonist Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.528 by -$0.022.

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate is -0.61.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 62,211,320 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Protagonist Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.528. Following the earnings report the stock price went down -5.384%.

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in PTGX

Protagonist Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

8.61%

Trailing 12-Months

Asset Growth

16.82%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel peptide-based therapeutics for the treatment of various diseases, particularly hematologic malignancies and autoimmune disorders. The company leverages its proprietary technology platform to design and optimize peptide drugs that aim to address unmet medical needs in these therapeutic areas.

Protagonist Therapeutics (PTGX) Earnings & Revenues

Historic Earnings Reports

PTGX Stock 12 Month Forecast

Average Price Target

$69.20

▲(23.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","83":"$83","47.75":"$47.8","59.5":"$59.5","71.25":"$71.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$54.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,47.75,59.5,71.25,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.83,55.996923076923075,58.16384615384615,60.33076923076923,62.497692307692304,64.66461538461539,66.83153846153846,68.99846153846154,71.16538461538461,73.3323076923077,75.49923076923076,77.66615384615385,79.83307692307693,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.83,55.012307692307694,56.19461538461538,57.37692307692308,58.559230769230766,59.74153846153846,60.923846153846156,62.106153846153845,63.28846153846154,64.47076923076924,65.65307692307692,66.83538461538461,68.01769230769231,{"y":69.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.83,53.84307692307692,53.856153846153845,53.86923076923077,53.88230769230769,53.895384615384614,53.90846153846154,53.92153846153846,53.934615384615384,53.94769230769231,53.96076923076923,53.973846153846154,53.98692307692308,{"y":54,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.96,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.89,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.59,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >